SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.0891

Change

-0.01 (-8.43)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.49 (+0.70%)

USD 218.30B
AMGN Amgen Inc

+5.14 (+1.85%)

USD 151.21B
SNY Sanofi ADR

+0.36 (+0.69%)

USD 126.38B
GILD Gilead Sciences Inc

+2.67 (+2.46%)

USD 122.21B
BIIB Biogen Inc

+5.22 (+4.09%)

USD 17.35B
GRFS Grifols SA ADR

+0.18 (+2.20%)

USD 5.91B
AMRN Amarin Corporation PLC

+0.39 (+3.45%)

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

+0.40 (+7.62%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.57% 20% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.57% 20% F 8% B-
Trailing 12 Months  
Capital Gain -69.90% 20% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.90% 20% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -29.32% 20% F 8% B-
Dividend Return -29.32% 20% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.88% 20% F 40% F
Risk Adjusted Return -66.81% 30% F 11% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector